Results 221 to 230 of about 85,022 (329)

Rapid Normalization of a Highly Thickened Pericardium by Chemotherapy in a Patient with T‐cell Acute Lymphoblastic Lymphoma [PDF]

, 2008
Fethi Kılıçaslan, Alev Akyol Erikçi, Ata Kırılmaz, Eralp Ulusoy, B.S. Cebeci, Ahmet Öztürk, Mehmet Dinçtürk   +6 more
openalex   +1 more source

Implementing Pre‐Emptive Pharmacogenetics: Impact of Early Pharmacogenetic Screening in a Pediatric Oncology Cohort of 1,151 Subjects

Clinical Pharmacology &Therapeutics, Volume 118, Issue 2, Page 438-448, August 2025.
In pediatric oncology, pharmacogenetic guidelines are underutilized and the potential impact of pre‐emptive pharmacogenetic screening remains largely unexplored despite this field's need for individualized approaches. While comprehensive pharmacogenetic guidelines are not yet available for all anticancer drugs, evidence‐based recommendations exist for ...
Emma C. Bernsen, Eugène T.P. Verwiel, Maaike van der Lee, Jesse J. Swen, Marcel Santoso, Leiah J. Brigitha, Rick Admiraal, Bastiaan B.J. Tops, Alwin D.R. Huitema, Patrick Kemmeren, Jayne Y. Hehir‐Kwa, Lidwien M. Hanff, Meta H.M. Diekstra   +12 more
wiley   +1 more source

Combination of venetoclax with CHG regimen in refractory/relapsed T-lymphoblastic lymphoma/acute lymphoblastic leukemia: a case series and literature review. [PDF]

Discov Oncol
Zhou M, Yang Y, Zhang X, Jiao Y, Guo Z.
europepmc   +1 more source

Epstein-Barr virus-negative precursor B cell lymphoblastic lymphoma after liver transplantation: a unique form of posttransplant lymphoproliferative disease

, 2002
Elizabeth Borges, Judith A. Ferry, Alison M. Friedmann   +2 more
openalex   +1 more source

Minimal Disseminated Disease in Childhood T-Cell Lymphoblastic Lymphoma: A Report From the Children's Oncology Group [PDF]

, 2009
Elaine Coustan‐Smith, John T. Sandlund, Sherrie L. Perkins, Helen Chen, Myron Chang, Minnie Abromowitch, Dario Campana   +6 more
openalex   +1 more source

Characterization of Apixaban Pharmacokinetics/Pharmacodynamics and Dose Assessment in Pediatric Patients with Congenital or Acquired Heart Disease

Clinical Pharmacology &Therapeutics, Volume 118, Issue 2, Page 365-377, August 2025.
Apixaban is an oral direct inhibitor of factor Xa (FXa) that could be a treatment option for thromboembolism prevention in children with congenital or acquired heart disease (CAHD). Data from SAXOPHONE, a phase II pediatric study, were used to update a previously developed population pharmacokinetics (PPK) model and to assess the covariate effect of ...
Antoinette Ajavon‐Hartmann, Praneeth Jarugula, Hyunmoon Back, Obinna Obianom, Elizabeth Ludwig, Christina Crevar, David Marchisin, Zhaoqing Wang, Weidong Chen, Bing He, R. Mark Payne, Kristin M. Burns, Andrew C. Glatz, Christoph Male, Paul Monagle, Vidya Perera, Bindu Murthy, Samira Merali   +17 more
wiley   +1 more source

Multi‐omics integration analysis identifies INPP4B as a T‐cell‐specific activation suppressor

Clinical and Translational Medicine, Volume 15, Issue 8, August 2025.
A comprehensive multi‐omics characterisation of INPP4B across immune cell populations. Discovery of a T‐cell‐specific expression and interaction domain of INPP4B. INPP4B functions as a T‐cell‐specific activation suppressor. INPP4B is upregulated in exhausted T cells within the tumour microenvironment. Abstract Background Naïve T cells are maintained in
Ting Peng, Qing Fang, Zihao Zhao, Yingjun Chang, Xiangyu Zhao, Cheng Li   +5 more
wiley   +1 more source

Th1, Th2, and activated T-cell marker and clinical prognosis in peripheral T-cell lymphoma, unspecified: comparison with AILD, ALCL, lymphoblastic lymphoma, and ATLL

, 2003
Takeshi Tsuchiya, Koichi Ohshima, Kennosuke Karube, Takahiro Yamaguchi, Hiroaki Suefuji, Makoto Hamasaki, Chika Kawasaki, Junji Suzumiya, Masao Tomonaga, Masahiro Kikuchi   +9 more
openalex   +1 more source

Expression Profiling of Transcription Factors in B- or T-Acute Lymphoblastic Leukemia/Lymphoma and Burkitt Lymphoma [PDF]

, 2009
Michel R. Nasr, Nancy S. Rosenthal, Sergei Syrbu   +2 more
openalex   +1 more source

Efficacy and mechanism of the XPO1 inhibitor selinexor combined with decitabine in T-cell lymphoblastic lymphoma. [PDF]

Ann Hematol
Meng M, Feng X, Zhang Y, Gao Y, Han L, Li Z, Zhang X, Zhang M.   +7 more
europepmc   +1 more source